Form 4: Equillium Director Barbara Troupin Reports Option Repricing and Resulting Transactions

Director Barbara Troupin reports transactions related to the repricing of stock options, resulting in adjustments to derivative security holdings.

Summary

• Barbara Troupin, a director of Equillium, Inc., filed a Form 4 detailing changes in beneficial ownership.
• The filing reports transactions related to the repricing of stock options, which became effective on February 14, 2025.
• The repricing, approved by the Board of Directors on August 7, 2023, was based on the closing price of the company's common stock on August 14, 2023.
• The exercise price of the options was lowered to $0.785 per share.
• Troupin disposed of options with an exercise price of $3.59 and acquired options with an exercise price of $0.785.
• The options vest in 36 equal monthly installments following the grant date of March 1, 2022, and expire on February 29, 2032.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document simply reports a required filing related to option repricing, which is a fairly common corporate action. There's no inherent positive or negative implication without further context.

Industry Context

Stock option repricing is a mechanism companies use to re-incentivize employees or directors when the stock price has fallen significantly below the original option exercise price. It's a fairly common practice, especially in volatile markets, to keep key personnel motivated.

Comparison to Industry Standards

• Option repricing is a common practice in the biotech industry, especially for companies with volatile stock prices.
• Many companies, such as Amgen, Gilead Sciences, and Biogen, have used similar strategies to retain and incentivize key personnel.
• The specific terms of option grants and repricings (vesting schedules, exercise prices, etc.) vary widely based on company-specific factors and market conditions.

Stakeholder Impact

• The repricing of stock options could potentially impact shareholder value, depending on the future performance of the company's stock.
• It is designed to re-incentivize a key director, which could indirectly benefit shareholders if it leads to improved company performance.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Options, Repricing, Equillium, Director, Troupin, EQ